NASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free DMAC Stock Alerts $2.60 +0.01 (+0.39%) (As of 10:58 AM ET) Add Compare Share Share Today's Range$2.58▼$2.6050-Day Range$2.37▼$3.2052-Week Range$1.58▼$4.75Volume6,539 shsAverage Volume39,286 shsMarket Capitalization$98.70 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DiaMedica Therapeutics alerts: Email Address DiaMedica Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside170.3% Upside$7.00 Price TargetShort InterestHealthy0.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector634th out of 924 stocksPharmaceutical Preparations Industry285th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.46% of the outstanding shares of DiaMedica Therapeutics have been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in DiaMedica Therapeutics has recently decreased by 13.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMAC. Previous Next 2.6 News and Social Media Coverage News SentimentDiaMedica Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for DiaMedica Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.20% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.12% of the stock of DiaMedica Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About DiaMedica Therapeutics Stock (NASDAQ:DMAC)DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More DMAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMAC Stock News HeadlinesMay 2, 2024 | finance.yahoo.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | businesswire.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.May 1, 2024 | finance.yahoo.comBullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of StockApril 26, 2024 | americanbankingnews.comDiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated at Craig HallumApril 17, 2024 | businesswire.comDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeMarch 25, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.March 22, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | investorplace.comDMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023March 19, 2024 | benzinga.comRecap: DiaMedica Therapeutics Q4 EarningsMarch 19, 2024 | businesswire.comDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsMarch 6, 2024 | ca.finance.yahoo.comTryp Therapeutics Inc. (TRYP.CN)February 9, 2024 | benzinga.comDiaMedica Therapeutics Stock (NASDAQ:DMAC) Dividends: History, Yield and DatesJanuary 29, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceJanuary 7, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%December 11, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn SituationNovember 15, 2023 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)November 14, 2023 | finance.yahoo.comQ3 2023 DiaMedica Therapeutics Inc Earnings CallNovember 14, 2023 | gurufocus.comDiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2mNovember 13, 2023 | msn.comDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.01November 13, 2023 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNovember 10, 2023 | benzinga.comEarnings Outlook For DiaMedica TherapeuticsNovember 9, 2023 | finance.yahoo.comDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023See More Headlines Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/02/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMAC CUSIPN/A CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+170.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.07% Return on Assets-37.90% Debt Debt-to-Equity RatioN/A Current Ratio19.27 Quick Ratio19.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book1.92Miscellaneous Outstanding Shares37,960,000Free Float35,225,000Market Cap$98.32 million OptionableOptionable Beta1.69 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Dietrich John Pauls MBA (Age 53)President, CEO & Director Comp: $818.61kMr. Scott Kellen CPA (Age 59)CFO & Corporate Secretary Comp: $485.43kDr. Kirsten L. Gruis M.D. (Age 51)M.S., Independent Consultant Comp: $449.29kDr. Ambarish Shah Ph.D.Chief Technology OfficerMr. Dominic R. Cundari (Age 73)Chief Commercial Officer Mr. David J. Wambeke (Age 40)Chief Business Officer Dr. Lorianne K. Masuoka M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSCellectar BiosciencesNASDAQ:CLRBIO BiotechNASDAQ:IOBTAdageneNASDAQ:ADAGAnixa BiosciencesNASDAQ:ANIXView All CompetitorsInsiders & InstitutionsParagon Associates & Paragon Associates II Joint VentureBought 30,000 shares on 2/15/2024Ownership: 1.318%Avantax Advisory Services Inc.Bought 12,500 shares on 2/7/2024Ownership: 0.033%Simplex Trading LLCSold 500 shares on 2/2/2024Ownership: 0.000%Koch Thomas VonBought 1,470,588 shares on 6/23/2023Total: $5.00 M ($3.40/share)David J WambekeBought 38,364 shares on 6/23/2023Total: $150,003.24 ($3.91/share)View All Insider TransactionsView All Institutional Transactions DMAC Stock Analysis - Frequently Asked Questions Should I buy or sell DiaMedica Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DMAC shares. View DMAC analyst ratings or view top-rated stocks. What is DiaMedica Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued twelve-month price targets for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price. View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts. How have DMAC shares performed in 2024? DiaMedica Therapeutics' stock was trading at $2.84 at the beginning of the year. Since then, DMAC shares have decreased by 8.8% and is now trading at $2.59. View the best growth stocks for 2024 here. Are investors shorting DiaMedica Therapeutics? DiaMedica Therapeutics saw a decrease in short interest in April. As of April 15th, there was short interest totaling 175,400 shares, a decrease of 13.3% from the March 31st total of 202,200 shares. Based on an average daily trading volume, of 39,600 shares, the short-interest ratio is currently 4.4 days. View DiaMedica Therapeutics' Short Interest. When is DiaMedica Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our DMAC earnings forecast. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc. (NASDAQ:DMAC) issued its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE). When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are DiaMedica Therapeutics' major shareholders? DiaMedica Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David J Wambeke, Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DMAC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTrackerTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
